BR0214809A - Compostos de pirimidina - Google Patents
Compostos de pirimidinaInfo
- Publication number
- BR0214809A BR0214809A BR0214809-9A BR0214809A BR0214809A BR 0214809 A BR0214809 A BR 0214809A BR 0214809 A BR0214809 A BR 0214809A BR 0214809 A BR0214809 A BR 0214809A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- independently
- pyrimidine compounds
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- -1 PYRIMIDINE COMPOUNDS Chemical class 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 238000012261 overproduction Methods 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTOS DE PIRIMIDINA". A presente invenção refere-se a compostos de pirimidina de fórmula (I): R~ 1~ é a fórmula (II), arila ou heteroarila; cada um de R~ 2~ e R~ 4~ é independentemente R^ c^, halogênio, nitro, ciano, isotionitro, SR^ c^ ou OR^ c^; ou R~ 2~ e R~ 4~, tomados juntos, são carbonila; R~ 3~ é R^ c^, alquenila, alquinila, OR^ c^, OC(O)R^ c^, SO~ 2~R^ c^, S(O)R^ c^, S(O~ 2~)NR^ c^R^ d^, SR^ c^, NR^ c^R^ d^, NR^ c^COR^ d^, NR^ c^C(O)OR^ d^, NR^ c^C(O)NR^ c^R^ d^, NR^ c^SO~ 2~R^ d^, COR^ c^, C(O)OR^ c^ ou C(O)NR^ c^R^ d^; R~ 5~ ou alquila; n é 0, 1, 2, 3, 4, 5 ou 6; X é O, S, S(O), S(O~ 2~) ou NR^ c^; Y é uma ligação covalente, CH~ 2~, C(O), C=N-R^ c^, C=N-OR^ c^, C=N-SR^ c^, O, S, S(O), S(O~ 2~) ou NR^ c^; Z é N ou CH; um de U e V é N, e o outro é CR^ c^; e W é O, S, S(O), S(O~ 2~), NR^ c^ ou NC(O)R^ c^; onde cada um de R^ c^ e R^ b^ é independentemente H, alquila, arila, heteroarila; e cada um de R^ c^ e R^ d^ é independentemente H, alquila, arila, heteroarila, ciclila, heterociclila ou alquilcarbonila. Os compostos são úteis para tratar doenças relacionadas com a superprodução de IL-12 (por exemplo, artrite reumatóide, sepse, doença de Crohn, esclerose múltipla, psoríase ou diabetes mellitus dependente de insulina).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/000,742 US6693097B2 (en) | 2001-11-30 | 2001-11-30 | Pyrimidine compounds |
| US10/192,347 US6660733B2 (en) | 2001-11-30 | 2002-07-10 | 2,4,6-trisubstituted-pyrimidine compounds |
| PCT/US2002/038161 WO2003047516A2 (en) | 2001-11-30 | 2002-11-27 | Pyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0214809A true BR0214809A (pt) | 2004-09-14 |
Family
ID=26668093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0214809-9A BR0214809A (pt) | 2001-11-30 | 2002-11-27 | Compostos de pirimidina |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6958332B2 (pt) |
| EP (1) | EP1458687B1 (pt) |
| JP (1) | JP2005519034A (pt) |
| KR (1) | KR100950122B1 (pt) |
| CN (1) | CN100349876C (pt) |
| AU (1) | AU2002357033B2 (pt) |
| BR (1) | BR0214809A (pt) |
| CA (1) | CA2468349A1 (pt) |
| IL (1) | IL162189A0 (pt) |
| IS (1) | IS7287A (pt) |
| MX (1) | MXPA04005181A (pt) |
| NO (1) | NO328144B1 (pt) |
| NZ (1) | NZ533437A (pt) |
| RU (1) | RU2320658C2 (pt) |
| TW (1) | TWI256953B (pt) |
| WO (1) | WO2003047516A2 (pt) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005519034A (ja) * | 2001-11-30 | 2005-06-30 | シンタ ファーマシューティカルズ コーポレーション | ピリミジン化合物 |
| US6693097B2 (en) * | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| CA2502356A1 (en) * | 2002-10-15 | 2004-04-29 | Synta Pharmaceuticals Corp. | Aromatic bicyclic heterocyles to modulate 1l - 12 production |
| EP1689403A4 (en) * | 2003-11-10 | 2007-09-05 | Synta Pharmaceuticals Corp | HETEROARYL-hydrazone compounds |
| EP1687002A4 (en) * | 2003-11-10 | 2008-07-23 | Synta Pharmaceuticals Corp | CONDENSED HETEROCYCLIC COMPOUNDS |
| EP1687004A4 (en) | 2003-11-10 | 2009-04-08 | Synta Pharmaceuticals Corp | PYRIDINE COMPOUNDS |
| US20050282232A1 (en) * | 2003-11-10 | 2005-12-22 | Rongzhen Lu | Compositions and methods for modulating c-Rel-dependent cytokine production |
| US7745436B2 (en) * | 2004-04-13 | 2010-06-29 | Synta Pharmaceuticals Corporation | Disalt inhibitors of IL-12 production |
| AU2005262322B2 (en) * | 2004-07-01 | 2012-07-26 | Synta Pharmaceuticals Corp. | 2-substituted heteroaryl compounds |
| CA2579143A1 (en) | 2004-09-13 | 2006-03-23 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
| WO2006053112A1 (en) * | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Process for preparing trisubstituted pyrimidine compounds |
| WO2006053109A1 (en) * | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
| TW200628159A (en) * | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
| WO2006060194A1 (en) * | 2004-11-19 | 2006-06-08 | Synta Pharmaceuticals Corp. | Pyrimidine compounds and uses thereof |
| WO2006128172A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating b cell regulated autoimmune disorders |
| TW200804307A (en) * | 2005-10-27 | 2008-01-16 | Synta Pharmaceuticals Corp | Process for preparing mesylate salts of IL-12 inhibitory compounds |
| US8288398B2 (en) * | 2005-12-08 | 2012-10-16 | Merck Serono Sa | Antiproliferative pyrimidyl, fused pyrimidyl and pyrimidyl hydrazones |
| WO2008110891A2 (en) * | 2007-03-09 | 2008-09-18 | Orchid Research Laboratories Limited, | New heterocyclic compounds |
| US20110098267A1 (en) * | 2008-02-07 | 2011-04-28 | Synta Pharmaceuticals Corporation | Topical formulations for the treatment of psoriasis |
| KR101581828B1 (ko) | 2008-03-07 | 2015-12-31 | 아지엔드 키미쉐 리유나이트 안젤리니 프란체스코 에이.씨.알.에이.에프. 에스.피.에이 | 신규한 1-벤질-3-하이드록시메틸인다졸 유도체들 및 ｍｃｐ-1, ｃｘ3ｃｒ1 및 ｐ40의 발현을 기초로 한 질환들의 치료에서 이의 용도 |
| EP2262778B8 (en) | 2008-03-07 | 2020-01-01 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| WO2010074284A1 (ja) | 2008-12-26 | 2010-07-01 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| JPWO2011078221A1 (ja) * | 2009-12-24 | 2013-05-09 | 味の素株式会社 | イミダゾピリダジン化合物 |
| CN103052628B (zh) | 2010-07-20 | 2016-05-18 | 韦斯塔隆公司 | 三嗪类和嘧啶类杀虫剂 |
| CN105963300B (zh) * | 2015-03-13 | 2019-06-11 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | PIKfyve抑制剂抗辐射损伤的用途 |
| CN106279041A (zh) * | 2016-08-16 | 2017-01-04 | 四川思睿博生物科技有限公司 | 苯基嘧啶衍生物及其制备方法和用途 |
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| AU2019223014B2 (en) | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| WO2023118896A1 (en) | 2021-12-23 | 2023-06-29 | Subintro Limited | Novel antiviral compositions comprising oleic acid |
| CN118852327A (zh) * | 2023-04-13 | 2024-10-29 | 中国科学院上海有机化学研究所 | 一类PIKfyve蛋白激酶降解剂及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9116039D0 (en) * | 1991-07-25 | 1991-09-11 | Ucb Sa | Substituted cyclopropylamino-1,3,5-triazines |
| US6830751B1 (en) * | 1994-03-14 | 2004-12-14 | Genetics Institute, Llc | Use of IL-12 antagonists in the treatment of rheumatoid arthritis |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| NZ513639A (en) * | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| US6384032B1 (en) * | 1999-06-17 | 2002-05-07 | Shionogi Bioresearch Corp. | Inhibitors of IL-12 production |
| ATE449764T1 (de) * | 1999-12-28 | 2009-12-15 | Pharmacopeia Inc | Cytokine, insbesondere tnf-alpha, hemmer |
| US6525051B2 (en) * | 2000-03-27 | 2003-02-25 | Schering Aktiengesellschaft | N-heterocyclic derivatives as NOS inhibitors |
| US6680315B2 (en) * | 2000-06-15 | 2004-01-20 | Synta Pharmaceuticals Corp. | Triazine compounds |
| JP2005519034A (ja) * | 2001-11-30 | 2005-06-30 | シンタ ファーマシューティカルズ コーポレーション | ピリミジン化合物 |
| US6693097B2 (en) * | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| EP1689403A4 (en) * | 2003-11-10 | 2007-09-05 | Synta Pharmaceuticals Corp | HETEROARYL-hydrazone compounds |
-
2002
- 2002-11-27 JP JP2003548777A patent/JP2005519034A/ja not_active Withdrawn
- 2002-11-27 NZ NZ533437A patent/NZ533437A/en not_active IP Right Cessation
- 2002-11-27 EP EP02804468A patent/EP1458687B1/en not_active Expired - Lifetime
- 2002-11-27 BR BR0214809-9A patent/BR0214809A/pt not_active IP Right Cessation
- 2002-11-27 KR KR1020047008313A patent/KR100950122B1/ko not_active Expired - Fee Related
- 2002-11-27 AU AU2002357033A patent/AU2002357033B2/en not_active Ceased
- 2002-11-27 CN CNB028239512A patent/CN100349876C/zh not_active Expired - Lifetime
- 2002-11-27 MX MXPA04005181A patent/MXPA04005181A/es active IP Right Grant
- 2002-11-27 WO PCT/US2002/038161 patent/WO2003047516A2/en not_active Ceased
- 2002-11-27 RU RU2004119853/04A patent/RU2320658C2/ru active IP Right Revival
- 2002-11-27 IL IL16218902A patent/IL162189A0/xx unknown
- 2002-11-27 CA CA002468349A patent/CA2468349A1/en not_active Abandoned
- 2002-11-29 TW TW091134807A patent/TWI256953B/zh not_active IP Right Cessation
-
2003
- 2003-09-05 US US10/655,672 patent/US6958332B2/en not_active Expired - Lifetime
-
2004
- 2004-05-26 IS IS7287A patent/IS7287A/is unknown
- 2004-06-29 NO NO20042742A patent/NO328144B1/no not_active IP Right Cessation
-
2005
- 2005-07-29 US US11/193,002 patent/US7470681B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7470681B2 (en) | 2008-12-30 |
| US6958332B2 (en) | 2005-10-25 |
| EP1458687A2 (en) | 2004-09-22 |
| NO20042742L (no) | 2004-08-24 |
| TWI256953B (en) | 2006-06-21 |
| RU2320658C2 (ru) | 2008-03-27 |
| EP1458687B1 (en) | 2012-01-11 |
| IL162189A0 (en) | 2005-11-20 |
| CN1599726A (zh) | 2005-03-23 |
| EP1458687A4 (en) | 2005-03-23 |
| WO2003047516A2 (en) | 2003-06-12 |
| KR100950122B1 (ko) | 2010-03-30 |
| TW200400190A (en) | 2004-01-01 |
| AU2002357033A1 (en) | 2003-06-17 |
| US20060030560A1 (en) | 2006-02-09 |
| KR20050058257A (ko) | 2005-06-16 |
| IS7287A (is) | 2004-05-26 |
| AU2002357033B2 (en) | 2009-05-07 |
| CA2468349A1 (en) | 2003-06-12 |
| CN100349876C (zh) | 2007-11-21 |
| RU2004119853A (ru) | 2006-01-10 |
| NZ533437A (en) | 2007-05-31 |
| US20040053937A1 (en) | 2004-03-18 |
| WO2003047516A3 (en) | 2003-07-31 |
| NO328144B1 (no) | 2009-12-14 |
| MXPA04005181A (es) | 2005-06-17 |
| JP2005519034A (ja) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE365551T1 (de) | Fusionierte heteroaryl-derivative zur verwendung als p38 kinase inhibitoren zur behandlung von u.a rheumatischer arthritis | |
| PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| WO2006032466A3 (en) | New bicyclic antibiotics | |
| ATE289623T1 (de) | 8-(anilino)-1-naphthalinsulfonatanaloge und ihre verwendung in analytendetektions-tests | |
| DE59508688D1 (de) | 2-[1',2',4'-triazol-3'yloxymethylen]-anilide und ihre verwendung als schädlingsbekämpfungsmittel | |
| WO2003097656A3 (en) | Novel substituted sulfamate anticonvulsant derivatives | |
| CY1109907T1 (el) | Διεργασια για την παρασκευη 2-αμινοθειαζολο-5- αρωματικων καρβοξαμιδιων ως αναστολεις κινασων | |
| ATE427932T1 (de) | 11beta-hsd1-inhibitoren | |
| NO20065830L (no) | Substituerte 2-kinolyloksazoler som er anvendbare som PDE4-inhibitorer. | |
| TWI256953B (en) | Pyrimidine compounds | |
| ATE368656T1 (de) | Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden | |
| NO20065178L (no) | Tienopyridinderivater | |
| TW200635585A (en) | Monocyclic substituted methanones | |
| EA200702073A1 (ru) | Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| ATE134364T1 (de) | Phenylthioharnstoffderivate und ihre pharmazeutische verwendung | |
| HUP0201475A2 (hu) | Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| DE60333546D1 (de) | PyrazoloÄ4,3-DÜpyrimidines, verfahren zur ihre herstellung und deren verwendung | |
| ATE553077T1 (de) | Peptidaseinhibitoren | |
| RU2008106251A (ru) | В-лактамилзамещенные аналоги фенилаланина, цистейна и серина в качестве антагонистов вазопрессина | |
| CY1108837T1 (el) | ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5 | |
| PE20061078A1 (es) | Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4) | |
| CY1107362T1 (el) | Παραγωγα ιμιδαζολυλιου χρησιμα ως συνδετες υποδοχεων ισταμινης h3 | |
| PE20061080A1 (es) | Compuestos derivados de piridotienopirimidina como inhibidores de fosfodiesterasa 4 | |
| WO2006029154A3 (en) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |